Drugs / [18F]FP-R01-MG-F2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03183570 | Nov 2017 → Apr 2023 | idiopathic pulmonary fibrosis, primary sclerosing cholangitis | Stanford University | Completed | No outcome recorded |
| Phase 0 | NCT02683824 | Jan 2016 → Sep 2021 | exocrine pancreatic carcinoma | Stanford University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]FP-R01-MG-F2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02683824 ↗ |
| Modality | Peptide | “A novel cystine-knot peptide-based PET radiopharmaceutical” PMID 34729628 ↗ Nov 2021 |
| Route | Intravenous | “Patients receive \[18F\]FP-R01-MG-F2 intravenously (IV)” NCT02683824 ↗ |